Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders

Bibliography

• Olney JW, Newcomer JW, Farber NB. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 1999;33(6):523-33
   PubMed Web of Science ®Google Scholar
• Lindstrom E, Bingefors K. Patient compliance with drug therapy in schizophrenia. Economic and clinical issues. Pharmacoeconomics 2000;18(2):106-24
   PubMed Web of Science ®Google Scholar
• Gray JA, Roth BL. The pipeline and future of drug development in schizophrenia. Mol Psychiatry 2007;12(10):904-22
   PubMed Web of Science ®Google Scholar
• Sun SX, Liu GG, Christensen DB, et al. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin 2007;23(10):2305-12
   PubMed Web of Science ®Google Scholar
• Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schizophr Bull 2004;30(2):279-93
   PubMed Web of Science ®Google Scholar
• Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 2004;3(4):353-9
   PubMed Web of Science ®Google Scholar
• Fink H, Morgenstern R, Oelssner W. Clozapine – a serotonin antagonist? Pharmacol Biochem Behav 1984;20(4):513-7
   PubMedGoogle Scholar
• Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 1989;251(1):238-46
   PubMed Web of Science ®Google Scholar
• Reynolds GP, Garrett NJ, Rupniak N, et al. Chronic clozapine treatment of rats down-regulates cortical 5-HT2 receptors. Eur J Pharmacol 1983;89(3-4):325-6
   PubMedGoogle Scholar
• Roth BL, Ciaranello RD, Meltzer HY. Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors. J Pharmacol Exp Ther 1992;260(3):1361-5
   PubMed Web of Science ®Google Scholar
• Roth BL, Craigo SC, Choudhary MS, et al. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 1994;268(3):1403-10
   PubMed Web of Science ®Google Scholar
• Matz R, Rick W, Thompson H, et al. Clozapine – a potential antipsychotic agent without extrapyramidal manifestations. Curr Ther Res Clin Exp 1974;16(7):687-95
   PubMed Web of Science ®Google Scholar
• Matz R, Rick W, Oh D, et al. Clozapine – a potential antipsychotic agent without extrapyramidal manifestations. Psychopharmacol Bull 1975;11(1):14
   PubMedGoogle Scholar
• Yokoi F, Grunder G, Biziere K, et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C] raclopride. Neuropsychopharmacology 2002;27(2):248-59
   PubMed Web of Science ®Google Scholar
• Nyberg S, Nakashima Y, Nordstrom AL, et al. Positron emission tomography of in vivo binding characteristics of atypical antipsychotic drugs. Review of D2 and 5-HT2 receptor occupancy studies and clinical response. Br J Psychiatry 1996;29(Suppl):40-4
   Google Scholar
• Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003;28(3):519-26
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209-23
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995;152(2):183-90
   PubMed Web of Science ®Google Scholar
• Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45(9):789-96
   PubMed Web of Science ®Google Scholar
• Kane JM, Honigfeld G, Singer J, et al. Clozapine in treatment-resistant schizophrenics. Psychopharmacol Bull 1988;24(1):62-7
   PubMedGoogle Scholar
• Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 1998;49(2):196-201
   PubMed Web of Science ®Google Scholar
• Mortimer A, Williams P, Meddis D. Impact of side-effects of atypical antipsychotics on non-compliance, relapse and cost. J Int Med Res 2003;31(3):188-96
   PubMed Web of Science ®Google Scholar
• Voruganti LP, Baker LK, Awad AG. New generation antipsychotic drugs and compliance behaviour. Curr Opin Psychiatry 2008;21(2):133-9
   PubMed Web of Science ®Google Scholar
• Hummer M, Huber J. Hyperprolactinaemia and antipsychotic therapy in schizophrenia. Curr Med Res Opin 2004;20(2):189-97
   PubMed Web of Science ®Google Scholar
• Howes OD, Smith S, Aitchison KJ. Comment on hyperprolactinaemia and antipsychotic therapy in schizophrenia. Curr Med Res Opin 2004;20(10):1649
   PubMed Web of Science ®Google Scholar
• Wallace M. Real progress – the patient's perspective. Int Clin Psychopharmacol 2001;16(Suppl1):S21-4
   Google Scholar
• Findley LJ. The economic impact of Parkinson's disease. Parkinsonism Relat Disord 2007;13(Suppl):S8-12
   PubMed Web of Science ®Google Scholar
• Huse DM, Schulman K, Orsini L, et al. Burden of illness in Parkinson's disease. Mov Disord 2005;20(11):1449-54
   PubMed Web of Science ®Google Scholar
• Guttman M, Slaughter PM, Theriault ME, et al. Burden of parkinsonism: a population-based study. Mov Disord 2003;18(3):313-9
   PubMed Web of Science ®Google Scholar
• Wint DP, Okun MS, Fernandez HH. Psychosis in Parkinson's disease. J Geriatr Psychiatry Neurol 2004;17(3):127-36
   PubMed Web of Science ®Google Scholar
• Friedman JH. Atypical antipsychotics in the EPS-vulnerable patient. Psychoneuroendocrinology 2003;28(Suppl 1):39-51
   PubMed Web of Science ®Google Scholar
• Hoeh N, Gyulai L, Weintraub D, et al. Pharmacologic management of psychosis in the elderly: a critical review. J Geriatr Psychiatry Neurol 2003;16(4):213-8
   PubMedGoogle Scholar
• Blin O. A comparative review of new antipsychotics. Can J Psychiatry 1999;44(3):235-44
   PubMed Web of Science ®Google Scholar
• Wafford KA, Ebert B. Emerging anti-insomnia drugs: tackling sleeplessness and the quality of wake time. Nat Rev Drug Discov 2008;7(6):530-40
   PubMed Web of Science ®Google Scholar
• Gaillard JM. Chronic primary insomnia: possible physiopathological involvement of slow wave sleep deficiency. Sleep 1978;1(2):133-47
   PubMedGoogle Scholar
• Gonzalez-Maeso J, Yuen T, Ebersole BJ, et al. Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex. J Neurosci 2003;23(26):8836-43
   PubMedGoogle Scholar
• Nichols CD, Sanders-Bush E. A single dose of lysergic acid diethylamide influences gene expression patterns within the mammalian brain. Neuropsychopharmacology 2002;26(5):634-42
   PubMed Web of Science ®Google Scholar
• Morairty SR, Hedley L, Flores J, et al. Selective 5HT2A and 5HT6 receptor antagonists promote sleep in rats. Sleep 2008;31(1):34-44
   PubMed Web of Science ®Google Scholar
• Sharpley AL, Elliott JM, Attenburrow MJ, et al. Slow wave sleep in humans: role of 5-HT2A and 5-HT2C receptors. Neuropharmacology 1994;33(3-4):467-71
   PubMed Web of Science ®Google Scholar
• Nordstrom AL, Mansson M, Jovanovic H, et al. PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain. Int J Neuropsychopharmacol 2008;11(2):163-71
   PubMed Web of Science ®Google Scholar
• Vanover KE, Robbins-Weilert D, Wilbraham DG, et al. Pharmacokinetics, tolerability, and safety of ACP-103 following single or multiple oral dose administration in healthy volunteers. J Clin Pharmacol 2007;47(6):704-14
   PubMed Web of Science ®Google Scholar
• Vanover KE, Robbins-Weilert D, Wilbraham DG, et al. The effects of food on the pharmacokinetics of a formulated ACP-103 tablet in healthy volunteers. J Clin Pharmacol 2007;47(7):915-9
   PubMed Web of Science ®Google Scholar
• Acadia Pharmaceuticals, Press release, 24 April 2007
   Google Scholar
• Acadia Pharmaceuticals, Press release, 15 September 2004
   Google Scholar
• Acadia Pharmaceuticals, Press release, 1 December 2005
   Google Scholar
• Acadia Pharmaceuticals, Press release, 19 March 2007
   Google Scholar
• Acadia Pharmaceuticals, Press release, 23 March 2006
   Google Scholar
• Acadia Pharmaceuticals, Press release, 19 April 2006
   Google Scholar
• Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999;25(2):233-55
   PubMed Web of Science ®Google Scholar
• Roth BL, Hanizavareh SM, Blum AE. Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology (Berl) 2003
   Google Scholar
• McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006;163(4):600-10
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Arvanitis L, Bauer D, et al. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry 2004;161(6):975-84
   PubMed Web of Science ®Google Scholar
• Tandon R. Safety and tolerability: how do newer generation ‘atypical’ antipsychotics compare? Psychiatr Q 2002;73(4):297-311
   PubMed Web of Science ®Google Scholar